AO-176 in Multiple Solid Tumor Malignancies

This study will examine AO-176 monotherapy in patients with select advanced solid tumors for
which standard therapy proven to provide clinical benefit does not exist or is no longer
effective.

The study utilizes a classic 3+3 design, with enrollment of 3 patients per cohort and
expansion of the cohort in the event of a DLT. There will be up to 30 patients treated during
dose escalation.

Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be
recruited to further assess safety and evaluate preliminary efficacy of AO-176.

Inclusion Criteria

1. Select advanced solid tumor for which standard therapy proven to provide clinical
benefit does not exist, or is no longer effective.

2. Measurable disease

3. ECOG status 0-1

4. Resolution of prior-therapy-related adverse effects

5. Minimum of 2 weeks since last dose of cancer therapy

Exclusion Criteria:

1. Previous hypersensitivity reaction to treatment with another monoclonal antibody.

2. Prior treatment with a Check Point Inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4
weeks.

3. Prior treatment with a CD47 targeted therapy

4. Prior organ or stem cell transplant